Baader Bank Aktiengesellschaft Sells 18,452 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Baader Bank Aktiengesellschaft trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 55.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,000 shares of the company's stock after selling 18,452 shares during the period. Baader Bank Aktiengesellschaft's holdings in Hims & Hers Health were worth $363,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Raleigh Capital Management Inc. grew its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares during the period. GAMMA Investing LLC grew its holdings in Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company's stock worth $54,000 after purchasing an additional 2,152 shares during the period. Quest Partners LLC increased its stake in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company's stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. CWM LLC lifted its holdings in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 115.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company's stock valued at $110,000 after purchasing an additional 2,442 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Trading Up 9.9 %

HIMS stock traded up $3.37 during trading on Friday, reaching $37.33. The stock had a trading volume of 19,688,822 shares, compared to its average volume of 10,444,740. The firm has a market cap of $8.16 billion, a PE ratio of 84.85 and a beta of 1.31. The stock's 50 day moving average is $29.20 and its two-hundred day moving average is $22.57. Hims & Hers Health, Inc. has a 52 week low of $8.51 and a 52 week high of $37.96.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) EPS. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the firm's stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares of the company's stock, valued at $1,399,273.20. This trade represents a 73.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the transaction, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,256,067 shares of company stock worth $34,459,485 in the last 90 days. 17.71% of the stock is currently owned by insiders.

Analyst Ratings Changes

HIMS has been the subject of a number of analyst reports. Citigroup lowered Hims & Hers Health from a "neutral" rating to a "sell" rating and raised their price objective for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Needham & Company LLC raised their price target on Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a report on Monday, January 6th. Morgan Stanley began coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $42.00 price target on the stock. Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and reduced their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.